

# Aakriti Labs

3 Mahatma Gandhi Marg, Gandhi Nagar Mod Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661

www.aakritilabs.com

CIN NO.: U85195RJ2004PTC019563



Name : Mr. DIVAKAR JHA

Age/Gender: 46 Y/Male Patient ID : 012310210046

BarcodeNo:10102900

Referred By: Self

Registration No: 68643

Registered

: 21/Oct/2023 12:58PM

Analysed

: 24/Oct/2023 02:23PM

Reported

: 24/Oct/2023 02:23PM

Panel

: MEDI WHEEL (ARCOFEMI

HEALTHCARE LTD)

### DIGITAL X-RAY CHEST PA VIEW

Soft tissue shadow and bony cages are normal.

Trachea is central.

Bilateral lung field and both CP angle are clear.

Domes of diaphragm are normally placed.

Transverse diameter of heart appears with normal limits.

IMPRESSION:- NO OBVIOUS ABNORMALITY DETECTED.

partner

\*\*\* End Of Report \*\*\*

Page 1 of 1



Dr. Neera Mehta M.B.B.S.,D.M.R.D. RMCNO.005807/14853

ALPL policy mandates the film records to be maintained for a period of 3 months only. Kindly collect the films before this period.



CODE/NAME & ADDRESS: C000049066

AGILUS DIAGNOSTICS LIMITED-WEL WALK-INAAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO : **0251WJ001887**PATIENT ID : DIVAM211077251

CLIENT PATIENT ID: 012310210046 ABHA NO : AGE/SEX :46 Years Male
DRAWN :21/10/2023 12:58:00
RECEIVED :21/10/2023 13:03:17
REPORTED :24/10/2023 14:14:07

Test Report Status <u>Final</u> Results Biological Reference Interval Units

Н	AEMATOLOGY - CBC		
MEDI WHEEL FULL BODY HEALTH CHECK UP A	BOVE 40 MALE		
BLOOD COUNTS,EDTA WHOLE BLOOD			
HEMOGLOBIN (HB)  METHOD: CYANIDE FREE DETERMINATION	15.2	13.0 - 17.0	g/dL
RED BLOOD CELL (RBC) COUNT METHOD: ELECTRICAL IMPEDANCE	5.65 High	4.5 - 5.5	mil/μL
WHITE BLOOD CELL (WBC) COUNT METHOD: ELECTRICAL IMPEDANCE	8.00	4.0 - 10.0	thou/µL
PLATELET COUNT METHOD: ELECTRONIC IMPEDANCE	203	150 - 410	thou/μL
RBC AND PLATELET INDICES			
HEMATOCRIT (PCV)	47.7	40 - 50	%
METHOD: CALCULATED PARAMETER  MEAN CORPUSCULAR VOLUME (MCV)  METHOD: CALCULATED PARAMETER	84.0	83 - 101	fL
MEAN CORPUSCULAR HEMOGLOBIN (MCH)  METHOD: CALCULATED PARAMETER	26.9 Low	27.0 - 32.0	pg
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD: CALCULATED PARAMETER	31.9	31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW) METHOD: CALCULATED PARAMETER	14.2 High	11.6 - 14.0	%
MENTZER INDEX	14.9		
MEAN PLATELET VOLUME (MPV)  METHOD: CALCULATED PARAMETER	10.1	6.8 - 10.9	fL
WBC DIFFERENTIAL COUNT			
NEUTROPHILS  METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY	49	40 - 80	%
LYMPHOCYTES  METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY	41 High	20 - 40	%
MONOCYTES	05	2 - 10	%

Dr. Akansha Jain Consultant Pathologist





Page 1 Of 17



View Report





CODE/NAME & ADDRESS: C000049066 AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

**JAIPUR 302017** 9314660100

ACCESSION NO: 0251WJ001887 PATIENT ID : DIVAM211077251

CLIENT PATIENT ID: 012310210046

ABHA NO

AGE/SEX :46 Years DRAWN :21/10/2023 12:58:00 RECEIVED: 21/10/2023 13:03:17 REPORTED :24/10/2023 14:14:07

Test Report Status <u>Final</u>	Results	Biological Reference Interv	al Units
METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY			
EOSINOPHILS	05	1 - 6	%
METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY			
BASOPHILS	00	0 - 2	%
METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY			
ABSOLUTE NEUTROPHIL COUNT	3.92	2.0 - 7.0	thou/µL
METHOD: CALCULATED PARAMETER			
ABSOLUTE LYMPHOCYTE COUNT	3.28 High	1.0 - 3.0	thou/µL
METHOD: CALCULATED PARAMETER			
ABSOLUTE MONOCYTE COUNT	0.4	0.2 - 1.0	thou/µL
METHOD : CALCULATED PARAMETER			
ABSOLUTE EOSINOPHIL COUNT	0.4	0.02 - 0.50	thou/µL
METHOD : CALCULATED PARAMETER			
ABSOLUTE BASOPHIL COUNT	0 Low	0.02 - 0.10	thou/µL
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	1.2		
NEO INOTHIE EIPITHOCHE NAMO (NEK)	1.4		

#### <b>Interpretation(s)</h>

BLOOD COUNTS, EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed

leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13)

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients; A.-P. Yang, et al.; International Immunopharmacology 84 (2020)

This ratio element is a calculated parameter and out of NABL scope.







Page 2 Of 17





**REF. DOCTOR: SELF** 

CODE/NAME & ADDRESS: C000049066 AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

**PATIENT NAME: DIVAKAR JHA** 

**JAIPUR 302017** 9314660100

ACCESSION NO: 0251WJ001887 PATIENT ID : DIVAM211077251

CLIENT PATIENT ID: 012310210046

ABHA NO

AGE/SEX :46 Years DRAWN :21/10/2023 12:58:00 RECEIVED: 21/10/2023 13:03:17

REPORTED :24/10/2023 14:14:07

%

**Test Report Status** Results **Biological Reference Interval** Units <u>Final</u>

#### **HAEMATOLOGY**

#### MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE **BLOOD** 

10.4 High HBA1C Non-diabetic: < 5.7

> Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5Therapeutic goals: < 7.0 Action suggested : > 8.0 (ADA Guideline 2021)

METHOD: HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC)

ESTIMATED AVERAGE GLUCOSE(EAG) 251.8 High < 116.0 mg/dL

METHOD: CALCULATED PARAMETER

Dr. Akansha Jain **Consultant Pathologist** 





Page 3 Of 17



**REF. DOCTOR: SELF PATIENT NAME: DIVAKAR JHA** 

CODE/NAME & ADDRESS: C000049066 AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

1ATPUR 302017 9314660100

ACCESSION NO: 0251WJ001887 PATIENT ID : DIVAM211077251

CLIENT PATIENT ID: 012310210046 ABHA NO

AGE/SEX :46 Years Male :21/10/2023 12:58:00 DRAWN RECEIVED: 21/10/2023 13:03:17 REPORTED :24/10/2023 14:14:07

**Test Report Status** Results **Biological Reference Interval Final** Units

#### **MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD**

mm at 1 hr E.S.R 0 - 14

METHOD: AUTOMATED (PHOTOMETRICAL CAPILLARY STOPPED FLOW KINETIC ANALYSIS)"

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-<b>Used For</b>:

- 1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
- Diagnosing diabetes
- Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

- 1. eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.
- eAG gives an evaluation of blood glucose levels for the last couple of months.
   eAG is calculated as eAG (mg/dl) = 28.7 \* HbA1c 46.7

<b>HbA1c Estimation can get affected due to :</b>

- 1. Shortened Erythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss,hemolytic anemia) will falsely lower HbA1c test results.Fructosamine is recommended in these patients which indicates diabetes control over 15 days.
- 2. Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.
- 3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism,chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.
- 4. Interference of hemoglobinopathies in HbA1c estimation is seen in
- a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.
- b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)
  c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy
  ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-<br/>
  \*\*b>TEST DESCRIPTION</b>\*\*c-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change. <h>TEST INTERPRETATION</h>

<br/>
<br/> Pregnancy, Estrogen medication, Aging.
Finding a very accelerated ESR<b>(>100 mm/hour)</b> in patients with ill-defined symptoms directs the physician to search for a systemic disease

(Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis). In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum. <b > Decreased < /b > in: Polycythermia vera, Sickle cell anemia

#### <b>LIMITATIONS</b>

- <br/>b>False elevated</b> ESR : Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia
- <br/>
  <br/> salicylates)

#### REFERENCE:

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition.





Page 4 Of 17

View Report



CODE/NAME & ADDRESS: C000049066
AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO : **0251WJ001887**PATIENT ID : DIVAM211077251

CLIENT PATIENT ID: 012310210046

ABHA NO :

AGE/SEX :46 Years Male
DRAWN :21/10/2023 12:58:00
RECEIVED :21/10/2023 13:03:17
REPORTED :24/10/2023 14:14:07

Test Report Status <u>Final</u> Results Biological Reference Interval Units

#### **IMMUNOHAEMATOLOGY**

#### MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

#### **ABO GROUP & RH TYPE, EDTA WHOLE BLOOD**

ABO GROUP TYPE A

METHOD: TUBE AGGLUTINATION

RH TYPE POSITIVE

METHOD: TUBE AGGLUTINATION

<b>Interpretation(s)</b>

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

Dr. Akansha Jain Consultant Pathologist





Page 5 Of 17

View Details

View Report



CODE/NAME & ADDRESS: C000049066 AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100

ACCESSION NO: 0251WJ001887 PATIENT ID : DIVAM211077251

CLIENT PATIENT ID: 012310210046

ABHA NO

AGE/SEX :46 Years Male DRAWN :21/10/2023 12:58:00 RECEIVED: 21/10/2023 13:03:17 REPORTED :24/10/2023 14:14:07

**Test Report Status** Results **Biological Reference Interval** Units <u>Final</u>

**BIOCHEMISTRY** 

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

**GLUCOSE FASTING, FLUORIDE PLASMA** 

FBS (FASTING BLOOD SUGAR)

METHOD: GLUCOSE OXIDASE

214 High

74 - 99

mg/dL

**GLUCOSE, POST-PRANDIAL, PLASMA** 

PPBS(POST PRANDIAL BLOOD SUGAR)

361 High

70 - 140

mg/dL

LIPID PROFILE WITH CALCULATED LDL

CHOLESTEROL, TOTAL

METHOD: CHOLESTEROL OXIDASE

METHOD: GLUCOSE OXIDASE

161

< 200 Desirable

mg/dL

200 - 239 Borderline High

>/= 240 High

< 150 Normal

mg/dL

150 - 199 Borderline High

200 - 499 High

>/=500 Very High

METHOD: LIPASE/GPO-PAP NO CORRECTION

METHOD: DIRECT CLEARANCE METHOD

HDL CHOLESTEROL

CHOLESTEROL LDL

TRIGLYCERIDES

32 Low

81

129

240 High

< 40 Low

mg/dL

>/=60 High

mg/dL

< 100 Optimal

100 - 129

Near optimal/ above optimal

130 - 159

Borderline High

160 - 189 High

>/= 190 Very High

Desirable: Less than 130 Above Desirable: 130 - 159

mg/dL

Borderline High: 160 - 189

High: 190 - 219

Very high: > or = 220

METHOD: CALCULATED PARAMETER

NON HDL CHOLESTEROL

Dr. Akansha Jain

**Consultant Pathologist** 





Page 6 Of 17







CODE/NAME & ADDRESS: C000049066

AGILUS DIAGNOSTICS LIMITED-WEL WALK-INAAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO: **0251WJ001887**PATIENT ID : DIVAM211077251

CLIENT PATIENT ID: 012310210046

ABHA NO :

AGE/SEX :46 Years Male
DRAWN :21/10/2023 12:58:00
RECEIVED :21/10/2023 13:03:17
REPORTED :24/10/2023 14:14:07

Test Report Status <u>Final</u>	Results	Biological Reference I	nterval Units
VERY LOW DENSITY LIPOPROTEIN	48.0 High	= 30.0</th <th>mg/dL</th>	mg/dL
CHOL/HDL RATIO	5.0 High	3.3 - 4.4 Low Risk 4.5 - 7.0 Average Risk 7.1 - 11.0 Moderate Risk > 11.0 High Risk	J
LDL/HDL RATIO	2.5	0.5 - 3.0 Desirable/Lo 3.1 - 6.0 Borderline/M Risk >6.0 High Risk	

#### Interpretation(s)

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

	77
A.CAD with > 1 feature of high risk group	
B. CAD with > 1 feature of Very high risk	group or recurrent ACS (within 1 year) despite LDL-C < or =
50 mg/dl or polyvascular disease	
1. Established ASCVD 2. Diabetes with 2	major risk factors or evidence of end organ damage 3.
Familial Homozygous Hypercholesterolen	iia .
1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end organ	
damage. 3. CKD stage 3B or 4. 4. LDL >	190 mg/dl 5. Extreme of a single risk factor. 6. Coronary
Artery Calcium - CAC >300 AU. 7. Lipoj	protein a >/= 50mg/dl 8. Non stenotic carotid plaque
2 major ASCVD risk factors	
0-1 major ASCVD risk factors	
erosclerotic cardiovascular disease) Risk I	Factors
s in males and $>$ or $= 55$ years in females	3. Current Cigarette smoking or tobacco use
remature ASCVD	4. High blood pressure
	B. CAD with > 1 feature of Very high risk 50 mg/dl or polyvascular disease  1. Established ASCVD 2. Diabetes with 2 Familial Homozygous Hypercholesterolem  1. Three major ASCVD risk factors. 2. D damage. 3. CKD stage 3B or 4. 4. LDL > Artery Calcium - CAC > 300 AU. 7. Lipor 2 major ASCVD risk factors  0-1 major ASCVD risk factors  erosclerotic cardiovascular disease) Risk I

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

Risk Group	Treatment Goals		Consider Drug Therapy	
(1)	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
Extreme Risk Group Category A	<50 (Optional goal < OR = 30 )	< 80 (Optional goal <or 60)<="" =="" td=""><td>&gt;OR = 50</td><td>&gt;OR = 80</td></or>	>OR = 50	>OR = 80







Page 7 Of 17



View Report





CODE/NAME & ADDRESS: C000049066

AGILUS DIAGNOSTICS LIMITED-WEL WALK-INAAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO : **0251WJ001887**PATIENT ID : DIVAM211077251

CLIENT PATIENT ID: 012310210046

ABHA NO :

AGE/SEX :46 Years Male
DRAWN :21/10/2023 12:58:00
RECEIVED :21/10/2023 13:03:17
REPORTED :24/10/2023 14:14:07

#### Test Report Status <u>Final</u> Results Biological Reference Interval Units

Extreme Risk Group Category B	<or 30<="" =="" th=""><th>&lt;OR = 60</th><th>&gt; 30</th><th>&gt;60</th></or>	<OR = 60	> 30	>60
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR= 100
Moderate Risk	<100	<130	>OR= 100	>OR= 130
Low Risk	<100	<130	>OR= 130*	>OR= 160

<sup>\*</sup>After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

#### LIVER FUNCTION PROFILE, SERUM

BILIRUBIN, TOTAL	0.74	0 - 1	mg/dL
METHOD: DIAZO WITH SULPHANILIC ACID			
BILIRUBIN, DIRECT	0.27 High	0.00 - 0.25	mg/dL
METHOD: DIAZO WITH SULPHANILIC ACID			
BILIRUBIN, INDIRECT	0.47	0.1 - 1.0	mg/dL
METHOD: CALCULATED PARAMETER			
TOTAL PROTEIN	8.7 High	6.4 - 8.2	g/dL
METHOD: BIURET REACTION, END POINT			
ALBUMIN	4.8 High	3.8 - 4.4	g/dL
METHOD: BROMOCRESOL GREEN			
GLOBULIN	3.9	2.0 - 4.1	g/dL
METHOD: CALCULATED PARAMETER			
ALBUMIN/GLOBULIN RATIO	1.2	1.0 - 2.1	RATIO
METHOD: CALCULATED PARAMETER			
ASPARTATE AMINOTRANSFERASE	43 High	0 - 37	U/L
(AST/SGOT)			
METHOD: TRIS BUFFER NO P5P IFCC / SFBC 37° C			
ALANINE AMINOTRANSFERASE (ALT/SGPT)	57 High	0 - 40	U/L
METHOD: TRIS BUFFER NO P5P IFCC / SFBC 37° C			
ALKALINE PHOSPHATASE	72	39 - 117	U/L
METHOD: AMP OPTIMISED TO IFCC 37° C			
GAMMA GLUTAMYL TRANSFERASE (GGT)	233 High	11 - 50	U/L
METHOD : GAMMA GLUTAMYL-3 CARBOXY-4 NITROANILIDE (IFCC	) 37° C		
LACTATE DEHYDROGENASE	395	230 - 460	U/L

#### **BLOOD UREA NITROGEN (BUN), SERUM**

BLOOD UREA NITROGEN 11 5.0 - 18.0 mg/dL

METHOD : UREASE KINETIC







Page 8 Of 17



View Report





CODE/NAME & ADDRESS: C000049066

AGILUS DIAGNOSTICS LIMITED-WEL WALK-INAAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO : **0251WJ001887**PATIENT ID : DIVAM211077251

CLIENT PATIENT ID: 012310210046

ABHA NO

AGE/SEX :46 Years Male
DRAWN :21/10/2023 12:58:00
RECEIVED :21/10/2023 13:03:17
REPORTED :24/10/2023 14:14:07

Test Report Status <u>Final</u> Results Biological Reference Interval Units

**CREATININE, SERUM** 

CREATININE 0.96 0.8 - 1.3 mg/dL

METHOD: ALKALINE PICRATE NO DEPROTEINIZATION

**BUN/CREAT RATIO** 

BUN/CREAT RATIO 11.46

METHOD: CALCULATED PARAMETER

URIC ACID, SERUM

URIC ACID 4.1 3.4 - 7.0 mg/dL

METHOD: URICASE PEROXIDASE WITH ASCORBATE OXIDASE

TOTAL PROTEIN, SERUM

TOTAL PROTEIN **8.7 High** 6.4 - 8.3 g/dL

METHOD: BIURET REACTION, END POINT

**ALBUMIN, SERUM** 

**ALBUMIN 4.8 High** 3.8 - 4.4 g/dL

 ${\tt METHOD: BROMOCRESOL\ GREEN}$ 

**GLOBULIN** 

GLOBULIN 3.9 2.0 - 4.1 g/dL

**ELECTROLYTES (NA/K/CL), SERUM** 

Dr. Akansha Jain Consultant Pathologist



Page 9 Of 17

View Details

View Report









AGE/SEX

**PATIENT NAME: DIVAKAR JHA REF. DOCTOR: SELF** 

CODE/NAME & ADDRESS: C000049066 AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

**JAIPUR 302017** 9314660100

ACCESSION NO: 0251WJ001887 PATIENT ID : DIVAM211077251

CLIENT PATIENT ID: 012310210046 ABHA NO

DRAWN :21/10/2023 12:58:00 RECEIVED: 21/10/2023 13:03:17 REPORTED :24/10/2023 14:14:07

:46 Years

Male

Test Report Status <u>Final</u>	Results	Biological Reference	Interval Units
SODIUM, SERUM	139.1	137 - 145	mmol/L
METHOD : ION-SELECTIVE ELECTRODE POTASSIUM, SERUM METHOD : ION-SELECTIVE ELECTRODE	4.78	3.6 - 5.0	mmol/L
CHLORIDE, SERUM  METHOD : ION-SELECTIVE ELECTRODE	98.0	98 - 107	mmol/L

#### Interpretation(s)

Sodium	Potassium	Chloride
Decreased in:CCF, cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy, adrenal insufficiency, nephrotic syndrome, water intoxication, SIADH. Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide, carbamazepine, anti depressants (SSRI), antipsychotics.	Decreased in: Low potassium intake, prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's syndrome, osmotic diuresis (e.g., hyperglycemia), alkalosis, familial periodic paralysis, trauma (transient). Drugs: Adrenergic agents, diuretics.	Decreased in: Vomiting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chronic respiratory acidosis diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenalinsufficiency, hyperaldosteronism, metabolic alkalosis. Drugs: chronic laxative, corticosteroids, diuretics.
Increased in: Dehydration (excessivesweating, severe vomiting or diarrhea),diabetes mellitus, diabetesinsipidus, hyperaldosteronism, inadequate water intake. Drugs: steroids, licorice,oral contraceptives.	Increased in: Massive hemolysis, severe tissue damage, rhabdomyolysis, acidosis, dehydration, renal failure, Addison's disease, RTA type IV, hyperkalemic familial periodic paralysis. Drugs: potassium salts, potassium- sparing diuretics, NSAIDs, beta-blockers, ACE inhibitors, highdose trimethoprim-sulfamethoxazole.	Increased in: Renal failure, nephrotic syndrome, RTA,dehydration, overtreatment with saline,hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (Loss of HCO3-), respiratory alkalosis,hyperadrenocorticism. Drugs: acetazolamide,androgens, hydrochlorothiazide,salicylates.
Interferences: Severe lipemia or hyperproteinemi, if sodium analysis involves a dilution step can cause spurious results. The serum sodium falls about 1.6 mEq/L for each 100 mg/dL increase in blood glucose.	Interferences: Hemolysis of sample, delayed separation of serum, prolonged fist clenching during blood drawing, and prolonged tourniquet placement. Very high WBC/PLT counts may cause spurious. Plasma potassium levels are normal.	Interferences: Test is helpful in assessing normal and increased anion gap metabolic acidosis and in distinguishing hypercalcemia due to hyperparathyroidism (high serum chloride) from that due to malignancy (Normal serum chloride)

<b>Interpretation(s)</b>

GLUCOSE FASTING, FLUORIDE PLASMA-<b>TEST DESCRIPTION</b>

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in

<br/>

insulin,ethanol,propranolol;sulfonylureas,tolbutamide,and other oral hypoglycemic agents.

<br/>
<br/> within individuals. Thus, glycosylated hemoglobin (HbA1c) levels are favored to monitor glycemic control.



**Consultant Pathologist** 





Page 10 Of 17









CODE/NAME & ADDRESS: C000049066 AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

1ATPUR 302017 9314660100

ACCESSION NO: 0251WJ001887 : DIVAM211077251

CLIENT PATIENT ID: 012310210046 ABHA NO

AGE/SEX :46 Years Male :21/10/2023 12:58:00 DRAWN RECEIVED: 21/10/2023 13:03:17 REPORTED :24/10/2023 14:14:07

**Test Report Status** Results **Biological Reference Interval Final** Units

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin

treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

<br/><b>Bilirubin</b> is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. cb>Elevated levels</b> results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin. <br/>
<br/

measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver,liver cancer,kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease,Rickets,Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia,Malnutrition,Protein deficiency,Wilsons disease.

<br/>
<br/> has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

<br/>
<

and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

<br/>

enteropathy,Burns,hemodilution,increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc BLOOD UREA NITROGEN (BUN), SERUM-<br/>
because of Increased clearance,malnutrition and wasting etc BLOOD UREA NITROGEN (BUN), SERUM-<br/>
catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism) <br/> <br/>b>Causes of decreased</b> level include Liver disease, SIADH.

CREATININE, SERUM-<b>Higher than normal level may be due to:</b>

• Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia) < b>Lower than normal level may be due to: </b> • Myasthenia Gravis, Muscuophy
URIC ACID, SERUM-<br/>
URIC ACID, SE

DM,Metabolic syndrome <br/>
TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum.Protein in the plasma is made up of albumin and globulin.<br/>
<br/>
<br/>
TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum.Protein in the plasma is made up of albumin and globulin.<br/>
<br/>
<br/> <br/>b>Lower-than-normal levels may be due to:</b> Agammaglobulinemia, Bleeding (hemorrhage),Burns,Glomerulonephritis, Liver disease, Malabsorption, Malnutrition,

Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. <b>Low blood albumin levels (hypoalbuminemia) can be caused by:</b> Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

Dr. Akansha Jain **Consultant Pathologist** 



Page 11 Of 17

View Details





CODE/NAME & ADDRESS: C000049066 AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100

ACCESSION NO: 0251WJ001887 PATIENT ID : DIVAM211077251

CLIENT PATIENT ID: 012310210046

ABHA NO

AGE/SEX :46 Years Male DRAWN :21/10/2023 12:58:00 RECEIVED: 21/10/2023 13:03:17

REPORTED :24/10/2023 14:14:07

**Test Report Status** Results Biological Reference Interval Units <u>Final</u>

#### **CLINICAL PATH - URINALYSIS**

#### MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

PHYSICAL EXAMINATION, URINE

PALE YELLOW COLOR

METHOD: GROSS EXAMINATION

**CLEAR** APPEARANCE

METHOD: GROSS EXAMINATION

#### CHEMICAL EXAMINATION, URINE

METHOD: PEROCIDASE ANTI PEROXIDASE

PH	5.0	4.7 - 7.5

METHOD: DOUBLE INDICATOR PRINCIPLE

<=1.005 1.003 - 1.035 SPECIFIC GRAVITY

METHOD: IONIC CONCENTRATION METHOD NOT DETECTED PROTFIN **NEGATIVE** 

METHOD: PROTEIN ERROR OF INDICATORS WITH REFLECTANCE

DETECTED (+) NOT DETECTED **GLUCOSE** 

METHOD: GLUCOSE OXIDASE PEROXIDASE / BENEDICTS NOT DETECTED KETONES NOT DETECTED

METHOD: SODIUM NITROPRUSSIDE REACTION

NOT DETECTED **NEGATIVE** BLOOD

NOT DETECTED NOT DETECTED **BILIRUBIN** 

METHOD : DIPSTICK UROBILINOGEN **NORMAL** NORMAL

METHOD: EHRLICH REACTION REFLECTANCE

NOT DETECTED NOT DETECTED NITRITE

METHOD: NITRATE TO NITRITE CONVERSION METHOD LEUKOCYTE ESTERASE NOT DETECTED NOT DETECTED

#### MICROSCOPIC EXAMINATION, URINE

/HPF RED BLOOD CELLS NOT DETECTED NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION PUS CELL (WBC'S) 1-2 0-5 /HPF

METHOD: DIPSTICK, MICROSCOPY

Dr. Akansha Jain

**Consultant Pathologist** 





Page 12 Of 17





NOT DETECTED

PATIENT NAME: DIVAKAR JHA REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000049066

AGILUS DIAGNOSTICS LIMITED-WEL WALK-INAAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO: **0251WJ001887**PATIENT ID : DIVAM211077251

CLIENT PATIENT ID: 012310210046

ABHA NO :

AGE/SEX :46 Years Male
DRAWN :21/10/2023 12:58:00
RECEIVED :21/10/2023 13:03:17
REPORTED :24/10/2023 14:14:07

	i	i	
Test Report Status <u>Final</u>	Results	Biological Reference I	Interval Units
EPITHELIAL CELLS	0-1	0-5	/HPF
METHOD: MICROSCOPIC EXAMINATION			
CASTS	NOT DETECTED		
METHOD: MICROSCOPIC EXAMINATION			
CRYSTALS	NOT DETECTED		
METHOD: MICROSCOPIC EXAMINATION			
BACTERIA	NOT DETECTED	NOT DETECTED	
METHOD: MICROSCOPIC EXAMINATION			

NOT DETECTED

#### Interpretation(s)

YEAST

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions
Proteins	Inflammation or immune illnesses
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind of kidney impairment
Glucose	Diabetes or kidney disease
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst
Urobilinogen	Liver disease such as hepatitis or cirrhosis
Blood	Renal or genital disorders/trauma
Bilirubin	Liver disease
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary tract infection and glomerular diseases
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either acute or chronic, polycystic kidney disease, urolithiasis, contamination by genital secretions
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or bladder catheters for prolonged periods of time
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal diseases







Page 13 Of 17



View Report







CODE/NAME & ADDRESS: C000049066 AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100

ACCESSION NO: 0251WJ001887 PATIENT ID : DIVAM211077251

CLIENT PATIENT ID: 012310210046

ABHA NO

AGE/SEX :46 Years :21/10/2023 12:58:00 DRAWN RECEIVED : 21/10/2023 13:03:17 REPORTED :24/10/2023 14:14:07

**Biological Reference Interval Test Report Status** <u>Final</u> Results Units

Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice
Uric acid	arthritis
Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis







Page 14 Of 17







CODE/NAME & ADDRESS: C000049066

AGILUS DIAGNOSTICS LIMITED-WEL WALK-INAAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO : **0251WJ001887**PATIENT ID : DIVAM211077251

CLIENT PATIENT ID: 012310210046

ABHA NO

AGE/SEX :46 Years Male
DRAWN :21/10/2023 12:58:00
RECEIVED :21/10/2023 13:03:17
REPORTED :24/10/2023 14:14:07

Test Report Status <u>Final</u> Results Biological Reference Interval Units

#### **CLINICAL PATH - STOOL ANALYSIS**

## MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE PHYSICAL EXAMINATION,STOOL

COLOUR

METHOD: GROSS EXAMINATION

SAMPLE NOT RECEIVED

Dr. Abhishek Sharma Consultant Microbiologist





Page 15 Of 17

View Details







CODE/NAME & ADDRESS: C000049066
AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO: **0251WJ001887**PATIENT ID : DIVAM211077251
CLIENT PATIENT ID: 012310210046

ABHA NO :

AGE/SEX :46 Years Male
DRAWN :21/10/2023 12:58:00
RECEIVED :21/10/2023 13:03:17
REPORTED :24/10/2023 14:14:07

Test Report Status Final Results Biological Reference Interval Units

#### **SPECIALISED CHEMISTRY - HORMONE**

### MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

#### THYROID PANEL, SERUM

ТЗ	83.62	60.0 - 181.0	ng/dL
METHOD : CHEMILUMINESCENCE			
T4	8.60	4.5 - 10.9	μg/dL
METHOD: CHEMILUMINESCENCE			
TSH (ULTRASENSITIVE)	2.373	0.550 - 4.780	μIU/mL
METHOD: CHEMILUMINESCENCE			

#### Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3) Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid hormone replacement therapy (3) In cases of Autoimmune/Hashimoto thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical inflammation, drugs like amphetamines, Iodine containing drug and dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre (3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4 replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism







Page 16 Of 17



View Report







CODE/NAME & ADDRESS: C000049066
AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO: **0251WJ001887**PATIENT ID: DIVAM211077251

CLIENT PATIENT ID: 012310210046

ABHA NO :

AGE/SEX :46 Years Male
DRAWN :21/10/2023 12:58:00
RECEIVED :21/10/2023 13:03:17
REPORTED :24/10/2023 14:14:07

Test Report Status <u>Final</u> Results Biological Reference Interval Units

6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2.Guidlines of the American Thyroid association duriing pregnancy and Postpartum, 2011. NOTE: It is advisable to detect Free T3,FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

\*\*End Of Report\*\*
Please visit www.agilusdiagnostics.com for related Test Information for this accession









View Report



Page 17 Of 17



3 Mahatma Gandhi Marg, Gandhi Nagar Mod Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661

www.aakritilabs.com

CIN NO.: U85195RJ2004PTC019563

Name : Mr. DIVAKAR JHA

Age/Gender: 46 Y/Male

Patient ID : 012310210046

BarcodeNo: 10102900

Referred By: Self

Registration No: 68643

Registered

: 21/Oct/2023 12:58PM

Analysed

: 24/Oct/2023 11:28AM

Reported

: 24/Oct/2023 11:29AM

Panel

: MEDI WHEEL (ARCOFEMI

HEALTHCARE LTD)

### USG: WHOLE ABDOMEN (Male)

LIVER

: Is normal in size with bright in echogenecity.

The IHBR and hepatic radicals are not dilated.

No evidence of focal echopoor/echorich lesion seen.

Portal vein diameter and common bile duct appear normal.

GALL

: Is normal in size, shape and echotexture. Walls are smooth and

regular with normal thickness. There is no evidence of cholelithiasis.

PANCREAS: Is normal in size, shape and echotexture. Pancreatic duct is not dilated. SPLEEN :Is normal in size, shape and echogenecity. Spleenic hilum is not dilated.

KIDNEYS: Right Kidney:-Size: 104 x 54 mm, Left Kidney:-Size: 110 x 60 mm.

Bilateral Kidneys are normal in size, shape and echotexture. corticomedullary differentiation is fair and ratio appears normal.

Pelvi calyceal system is normal. No evidence of hydronephrosis/ nephrolithiasis.

URINARY: Bladder walls are smooth, regular and normal thickness.

BLADDER: No evidence of mass or stone in bladder lumen.

PROSTATE: Is normal in size, shape and echotexture,

measures: 37 x 27 x 27 mm, wt:15 gms.

Its capsule is intact and no evidence of focal lesion.

SPECIFIC: No evidence of retroperitoneal mass or free fluid seen in peritoneal cavity. No evidence of lymphadenopathy or mass lesion in retroperitoneum.

Visualized bowel loop appear normal. Great vessels appear normal.

IMPRESSION :- Fatty liver

\*\*\* End Of Report \*\*\*

Page 1 of

Dr. Neera Mehta M.B.B.S., D.M.R.D.

RMCNO.005807/14853





## akriti Labs

Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661

www.aakritilabs.com

WINDOW- POOR/ADFOLIATE/GOODVALVE

CIN NO.: U85195RJ2004PTC019563

/AKAR JHA	AGE	46Y	SEX	MALE
HEEL HEALTH	DATE	24/10/2023	REG NO	
	HEEL HEALTH	HEEL HEALTH DATE		HEEL HEALTH DATE 24/10/2023 REG NO

MITRAL	NORMAL	TRICUSPID	NORMAL		
AORTIC	NORMAL	PULMONARY	NORMAL		

#### 2D/M-MOD

IVSD mm	9.1	IVSS mm	12.9	AORTA mm	24.0
LVID mm	47.7	LVIS mm	30.4	LA mm	28.8
LVPWD mm	9.5	LVPWS mm	13.2	EF%	60%

#### CHAMBERS

LA	NORMAL	RA	NORMAL	
LV	NORMAL	RV	NORMAL	
PERICARDIUM	NORMAL			

#### DOPPLER STUDY MITRAL

PEAK VELOCITY m/s E/A	0.75/0.90	PEAK GRADIANT MmHg	
MEAN VELOCITY m/s		MEAN GRADIANT MmHg	
MVA cm2 (PLANITMETERY)		MVA cm2 (PHT)	
MR			

#### AORTIC

PEAK VELOCITY m/s	1.17	PEAK GRADIANT MmHg
MEAN VELOCITY m/s		MEAN GRADIANT MmHg
AR		

#### TRICUSPID

PEAK VELOCITY m/s	0.53	PEAK GRADIANT MmHg	
MEAN VELOCITY m/s	V	MEAN GRADIANT MmHg	
TR		PASP mmHg	

#### **PULMONARY**

PEAK VELOCITY m/s	0.95	PEAK GRADIANT MmHg	
MEAN VELOCITY m/s		MEAN GRADIANT MmHg	
PR		RVEDP mmHg	

#### **IMPRESSION**

- LV DIASTOLIC DYSFUNCTION GRADE-1
- NORMAL LV SYSTOLIC FUNCTION
- **NO RWMA LVEF 60%**
- NORMAL RV FUNCTION
- NORMAL CHAMBER DIMENSIONS
- **NORMAL VALVULAR ECHO**
- INTACT IAS / IVS
- NO THROMBUS, NO VEGETATION, NORMAL PERICARDIUM.
- IVC NORMAL

CONCLUSION: DIASTOLIC DYSFUNCTION, FAIR LV FUNCTION.

